Infant Bacterial Therapeutics AB (publ) continues to recruit prematurely born infants to The Connection Study following a planned safety analysis. In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of the company drug candidate IBP-9414. The analysis was based on data from 1,403 babies in the ongoing Phase III study.

The recommendation from the DMC is that recruitment can continue as planned, in accordance with the approved study protocol. The study was initiated in July 2019 and is ongoing in the USA, Bulgaria, France, Hungary, Israel, Poland, Romania, Serbia, Spain, and the United Kingdom.